Growth Hormone (GH)

Lower values go with lower risk of death. No risk curve catalogued yet.

Published risk of death1.17×per SD increment of natural log of fasting hs-GH (95% CI 1.08–1.26) · Malmö Diet and Cancer study, Sweden, population-based, age 46-68 (mean 58), 59% women, examined 1991-1994

What studies found when this marker was changed

They describe what happened in those study groups, not a recommendation. See all catalogued interventions.

Measured changes in GH, study by study

1 effect with a numeric size, each from one study arm: the dot is the reported change, the line its 95% interval where one was given. Green points move the marker the way lower risk of death lies; amber the other way. Study results in the groups studied, not predictions for a person.

Each row is one study: what was changed, the effect it reported on this marker, and the source.
Type	Intervention	Reported effect	Evidence	Source
pharmacologic	Oral octreotide capsules for 36 weeks in patients with acromegaly previously controlled on injectable somatostatin receptor ligands	Mean GH 0.66 -> 0.60 ng/mL on oral octreotide vs 0.90 -> 2.57 ng/mL on placebo (withdrawal of SRL) over 36 weeks	RCT	Samson SL, Nachtigall LB, Fleseriu M, et al. Maintenance of Acromegaly Control…
pharmacologic	Oral growth hormone secretagogue MK-677 25 mg once daily for 7 days during a 14-day 18 kcal/kg/day caloric restriction in healthy volunteers	Peak GH response 22.6 +/- 9.3 micrograms/L after a week of dosing vs approximately 7 micrograms/L with placebo (single dose: 55.9 vs ~9 micrograms/L)	RCT	Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth…

Sources

Hallengren et al. Fasting levels of high-sensitivity growth hormone predict cardiovascular morbidity and mortality: the Malmö Diet and Cancer study. Journal of the American College of Cardiology. 2014;64:1452-60.